Literature DB >> 32270202

Modeling Variation in the Reproductive Lifespan of Female Adolescent and Young Adult Cancer Survivors Using AMH.

H Irene Su1, Brian Kwan2, Brian W Whitcomb3, Ksenya Shliakhsitsava4, Andrew C Dietz5, Shaylyn S Stark6, Elena Martinez7, Patrick M Sluss8, Mary D Sammel9, Loki Natarajan2.   

Abstract

CONTEXT: Many female survivors of adolescent and young adult cancers (AYA survivors) have shortened reproductive lifespans. However, the timing and duration of ovarian function after cancer treatment are largely unknown.
OBJECTIVE: To model the trajectory of ovarian function over two decades following cancer treatment and evaluate how trajectories vary by treatment gonadotoxicity and age.
DESIGN: In a prospective cohort, AYA survivors aged 18-39 at variable times since cancer treatment completion provided dried blood spots (DBS) every 6 months for up to 18 months. Anti-Müllerian hormone (AMH) levels were measured using the Ansh DBS AMH enzyme-linked immunosorbent assay. The mean AMH trajectory was modeled for the entire cohort and separately by treatment gonadotoxicity and age using functional principal components analysis.
RESULTS: 763 participants, mean (standard deviation) enrollment age 33.3 (4.7) and age at cancer diagnosis 25.9 (5.7) years, contributed 1905 DBS samples. The most common cancers were breast (26.9%), lymphoma (24.8%), and thyroid (18.0%). AMH trajectories differed among survivors by treatment gonadotoxicity (low, moderate, or high) (P < 0.001). Following low or moderately gonadotoxic treatments, AMH levels increased over 2-3 years and plateaued over 10-15 years before declining. In contrast, following highly gonadotoxic treatment, AMH levels were lower overall and declined shortly after peak at 2-3 years. Younger age at treatment was associated with higher trajectories, but a protective effect of younger age was not observed in survivors exposed to highly gonadotoxic treatments (Pinteraction < 0.001).
CONCLUSIONS: In this large AYA survivor cohort, timing and duration of ovarian function strongly depended on treatment gonadotoxicity and age at treatment. The findings provide novel, more precise information to guide reproductive decision-making. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  AMH; adolescent and young adult cancer; functional principal components analysis; ovarian reserve; reproductive lifespan

Mesh:

Substances:

Year:  2020        PMID: 32270202      PMCID: PMC7329316          DOI: 10.1210/clinem/dgaa172

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  52 in total

1.  Non-Hodgkin's lymphoma survivors' fertility and sexual function-related information needs.

Authors:  Camille T C Hammond; Ellen B Beckjord; Neeraj K Arora; Keith M Bellizzi; Diana D Jeffery; Noreen M Aziz
Journal:  Fertil Steril       Date:  2008-02-20       Impact factor: 7.329

2.  Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.

Authors:  Ian E Smith; Mitch Dowsett; Yoon-Sim Yap; Geraldine Walsh; Per E Lønning; Richard J Santen; Daniel Hayes
Journal:  J Clin Oncol       Date:  2006-06-01       Impact factor: 44.544

3.  Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study.

Authors:  Mark F H Brougham; Patricia M Crofton; Emma J Johnson; Nancy Evans; Richard A Anderson; W Hamish B Wallace
Journal:  J Clin Endocrinol Metab       Date:  2012-04-03       Impact factor: 5.958

4.  Longitudinal follow-up in female Childhood Cancer Survivors: no signs of accelerated ovarian function loss.

Authors:  A L F van der Kooi; M M van den Heuvel-Eibrink; A van Noortwijk; S J C M M Neggers; S M F Pluijm; E van Dulmen-den Broeder; W van Dorp; J S E Laven
Journal:  Hum Reprod       Date:  2016-11-07       Impact factor: 6.918

5.  Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve.

Authors:  M H van den Berg; A Overbeek; C B Lambalk; G J L Kaspers; D Bresters; M M van den Heuvel-Eibrink; L C Kremer; J J Loonen; H J van der Pal; C M Ronckers; W J E Tissing; A B Versluys; M van der Heiden-van der Loo; A C Heijboer; M Hauptmann; J W R Twisk; J S E Laven; C C M Beerendonk; F E van Leeuwen; E van Dulmen-den Broeder
Journal:  Hum Reprod       Date:  2018-08-01       Impact factor: 6.918

6.  Predicting age at menopause from serum antimüllerian hormone concentration.

Authors:  Fahimeh Ramezani Tehrani; Nezhat Shakeri; Masoud Solaymani-Dodaran; Fereidoun Azizi
Journal:  Menopause       Date:  2011-07       Impact factor: 2.953

7.  Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment.

Authors:  Christien Weenen; Joop S E Laven; Anne R M Von Bergh; Mark Cranfield; Nigel P Groome; Jenny A Visser; Piet Kramer; Bart C J M Fauser; Axel P N Themmen
Journal:  Mol Hum Reprod       Date:  2004-02       Impact factor: 4.025

Review 8.  The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count.

Authors:  Simone L Broer; Ben Willem J Mol; Dave Hendriks; Frank J M Broekmans
Journal:  Fertil Steril       Date:  2008-03-05       Impact factor: 7.329

9.  Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.

Authors:  Richard A Anderson; David A Cameron
Journal:  J Clin Endocrinol Metab       Date:  2011-02-16       Impact factor: 5.958

10.  Does AMH relate to timing of menopause? Results of an Individual Patient Data meta- analysis.

Authors:  M Depmann; M J C Eijkemans; S L Broer; F Ramezani Tehrani; M Solaymani-Dodaran; F Azizi; C B Lambalk; J F Randolph; S D Harlow; E W Freeman; M D Sammel; W M M Verschuren; Y T van der Schouw; B W Mol; F J M Broekmans
Journal:  J Clin Endocrinol Metab       Date:  2018-07-18       Impact factor: 5.958

View more
  11 in total

1.  Psychosocial stress and ovarian function in adolescent and young adult cancer survivors.

Authors:  Jayeon Kim; Brian W Whitcomb; Brian Kwan; David Zava; Patrick M Sluss; Andrew Dietz; Ksenya Shliakhtsitsava; Sally A D Romero; Loki Natarajan; H Irene Su
Journal:  Hum Reprod       Date:  2021-01-25       Impact factor: 6.918

2.  Long-term antimüllerian hormone patterns differ by cancer treatment exposures in young breast cancer survivors.

Authors:  Beth Zhou; Brian Kwan; Milli J Desai; Vinit Nalawade; Kathryn J Ruddy; Paul C Nathan; Henry J Henk; James D Murphy; Brian W Whitcomb; H Irene Su
Journal:  Fertil Steril       Date:  2022-02-23       Impact factor: 7.490

3.  Association between pregnancy intention and preconception health behaviors.

Authors:  Hena Naz Din; David Strong; Savitri Singh-Carlson; Heather L Corliss; Sheri J Hartman; Hala Madanat; H Irene Su
Journal:  Cancer       Date:  2021-10-11       Impact factor: 6.921

4.  The Use of AMH to Assess Ovarian Toxicity in Adolescents and Young Adults After Cancer Treatment.

Authors:  Richard A Anderson; W Hamish B Wallace
Journal:  J Clin Endocrinol Metab       Date:  2020-08-01       Impact factor: 5.958

5.  Family size and duration of fertility in female cancer survivors: a population-based analysis.

Authors:  Richard A Anderson; Tom W Kelsey; David S Morrison; W Hamish B Wallace
Journal:  Fertil Steril       Date:  2021-12-20       Impact factor: 7.329

6.  Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.

Authors:  Richard A Anderson; David Cameron; Florian Clatot; Isabelle Demeestere; Matteo Lambertini; Scott M Nelson; Fedro Peccatori
Journal:  Hum Reprod Update       Date:  2022-05-02       Impact factor: 17.179

7.  Beyond Premature Ovarian Insufficiency: Staging Reproductive Aging in Adolescent and Young Adult Cancer Survivors.

Authors:  Alexa C O Medica; Brian W Whitcomb; Ksenya Shliakhsitsava; Andrew C Dietz; Kelsey Pinson; Christina Lam; Sally A D Romero; Patrick Sluss; Mary D Sammel; H Irene Su
Journal:  J Clin Endocrinol Metab       Date:  2021-01-23       Impact factor: 5.958

Review 8.  Challenges in Measuring AMH in the Clinical Setting.

Authors:  Hang Wun Raymond Li; David Mark Robertson; Chris Burns; William Leigh Ledger
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-24       Impact factor: 5.555

9.  Theory-Guided Development of Fertility Care Implementation Strategies for Adolescent and Young Adult Cancer Survivors.

Authors:  Anna Dornisch; Emily H Yang; Jamie Gruspe; Erin R Roesch; Paula Aristizabal; Greg A Aarons; Teresa Helsten; Michelle B Takemoto; Sally A D Romero; Bonnie N Kaiser; Hui-Chun Irene Su
Journal:  J Adolesc Young Adult Oncol       Date:  2021-01-19       Impact factor: 1.757

Review 10.  The Clinical Value and Interpretation of Anti-Müllerian Hormone in Women With Cancer.

Authors:  Richard A Anderson; H Irene Su
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-07       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.